Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120402) titled 'Clinical Safety and Tolerability of Recombinant Anti-tetanus Toxin Monoclonal Antibody (Siltartoxatug) versus Human Tetanus Immunoglobulin for Post-traumatic Tetanus Passive Immunization: A Multicenter Study' on March 13.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Army Medical Center of PLA
Condition:
Tetanus Prophylaxis
Open Wounds
Trauma
Intervention:
Experimental group:Receive standard debridement + secukinumab (according to the dosage instructions, typically 10mg, administered via deep intramuscular injection).
Recruitment Status: Not Recruiting
Phase: 4 ...